Related Experiment Video
Updated: Jul 21, 2026

05:30
Controlled Cortical Impact Model for Traumatic Brain Injury
Published on: August 5, 2014
28.7K
Determining the Minimally Clinically Important Difference for the Disability Rating Scale in Persons With Chronic
Flora M Hammond1, Jessica M Ketchum2, Vipul Vinod Patni3
1Department of Physical Medicine and Rehabilitation, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Neurotrauma Reports
|July 21, 2023
Summary
The Disability Rating Scale (DRS) now has a minimally clinically important difference (MCID) of -1.0 point for chronic traumatic brain injury (TBI). This finding supports the DRS as a key outcome measure in TBI research and clinical trials.
Area of Science:
- Neuroscience
- Clinical Neurology
- Rehabilitation Medicine
Background:
- The Extended Glasgow Outcome Scale (GOSE) is the primary outcome in traumatic brain injury (TBI) studies.
- The Disability Rating Scale (DRS) assesses functional progress in chronic TBI.
- Establishing a minimally clinically important difference (MCID) for the DRS is crucial for its use in research.
Purpose of the Study:
- Determine the MCID for the DRS in chronic TBI.
- Establish the DRS change magnitude associated with a 1-point GOSE MCID.
Main Methods:
- Retrospective analysis of the Traumatic Brain Injury Model Systems National Database.
- Longitudinal data from 1, 2, and 5 years post-injury.
- Spearman's correlations to analyze DRS and GOSE relationships.
- Triangulation method using dynamic and static MCID estimates.
Main Results:
- A significant correlation was found between DRS and GOSE scores.
- Dynamic MCID estimate for DRS was -0.68 points.
- Exploratory static MCID estimate for DRS was -1.28 points.
- The final MCID for DRS, using triangulation, was calculated as -1.0 point.
Conclusions:
- A -1.0-point change on the DRS represents a minimally clinically important difference in chronic TBI.
- The established MCID supports the DRS as a viable alternative primary outcome measure for TBI research.
- This finding enhances the utility of the DRS in clinical trials and long-term TBI outcome studies.

